Usema 4mg Pre-filled Pen is administered as a once-weekly injection
[2] [3] The most common adverse reactions reported in clinical trials include nausea, diarrhea, vomiting, constipation, and abdominal painall gastrointestinal effects that occur in more than 5% of patients
Hypokalemia Risk of hypokalemia because of potential for topiramate to inhibit carbonic anhydrase
We know were repeating ourselves here, but this really is important: GLP-1 injections are regulated medicines that are supported by scientific evidence and GLP-1 patches are not
Our mission is to provide accessible, cutting-edge treatments to patients seeking to improve their health and quality of life
Given the frequent coexistence of obesity and T2D with cardiovascular disease and chronic kidney disease (CKD), incretin-based therapies (encompassing selective GLP-1 and multi-receptor agonists) have emerged as disease-modifying treatments across the cardiovascularkidneymetabolic (CKM) spectrum